Amgen Inc. with ticker code (AMGN) now have 23 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $350.61 and $156.85 calculating the mean target share price we have $284.64. (at the time of writing). Given that the stocks previous close was at $268.09 this now indicates there is a potential upside of 6.2%. The 50 day MA is $287.49 and the 200 day MA is $269.31. The market cap for the company is 143.55B. The stock price for the company is currently $267.86 USD
The potential market cap would be $152,413,099,791 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 21.45, revenue per share of $52.69 and a 6.29% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
